Kyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results, Beats Estimates By $0.09 EPS

Kyverna Therapeutics (NASDAQ:KYTX) issued its quarterly earnings results on Tuesday. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09, FiscalAI reports.

Kyverna Therapeutics Price Performance

KYTX stock traded down $0.11 during mid-day trading on Tuesday, reaching $10.23. The company’s stock had a trading volume of 612,894 shares, compared to its average volume of 861,134. The stock has a market cap of $619.22 million, a PE ratio of -2.80 and a beta of 2.05. The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.11. Kyverna Therapeutics has a fifty-two week low of $2.06 and a fifty-two week high of $13.67. The company’s 50 day moving average is $8.89 and its two-hundred day moving average is $8.30.

Institutional Trading of Kyverna Therapeutics

A number of hedge funds have recently bought and sold shares of KYTX. Adage Capital Partners GP L.L.C. acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at about $15,667,000. Balyasny Asset Management L.P. acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at about $9,220,000. Alyeska Investment Group L.P. acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at about $5,640,000. Heights Capital Management Inc. acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at about $2,555,000. Finally, Woodline Partners LP acquired a new stake in Kyverna Therapeutics in the 3rd quarter valued at about $1,513,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KYTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Kyverna Therapeutics in a research note on Thursday, April 23rd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kyverna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.67.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.